As such, we broadly annotated the known HNF1A in vivo spectrum, from benign to type 2 diabetes risk-modifying to HNF1A-MODY (inherited early-onset hyperglycemia, likely to be sulfonylurea-responsive based on MODY registry data), onto the principal components plots and dendrograms based on the spatial distribution of the variants along the in vitro data-derived functional spectrum, from wild-type/wild-type-like to intermediate to damaging (Figures 2 and 3). This evidence concerns the gene HNF1A and type 2 diabetes mellitus.